# LNZ100 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lnz100

> The FDA approved LNZ100, sponsored by LENZ Therapeutics, Inc. (LENZ), on July 31, 2025 for presbyopia in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is LNZ100 FDA approved?

Yes. The FDA approved LNZ100, sponsored by LENZ Therapeutics, Inc. (LENZ), on July 31, 2025 for presbyopia in adults. Press release filed with the SEC (EX-99): "•Announced FDA approval of VIZZ for the treatment of presbyopia on July 31, 2025 as the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States." [Calendar and source filings](https://sec-api.dev/pdufa/lnz100)

Source: Press release filed with the SEC (EX-99), accession 0001815776-25-000069, https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/lnz100#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | LNZ100 |
| Codes | LNZ100 |
| Sponsor | LENZ Therapeutics, Inc. (LENZ) https://sec-api.dev/companies/lenz/catalysts |
| Indications | [presbyopia in adults](https://sec-api.dev/indications/presbyopia-in-adults), [presbyopia](https://sec-api.dev/indications/presbyopia), presbyopia, a condition |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-19, last confirmed 2026-11-03.
- SEC Form 10-Q (accession 0001815776-26-000059): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm
- SEC Form 10-Q (accession 0001815776-26-000052): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/lenz-20260630.htm
- SEC Form 10-Q (accession 0001815776-26-000037): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000037/lenz-20260331.htm
- SEC Form 10-K (accession 0001815776-26-000011): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/lenz-20251231.htm
- SEC Form 10-Q (accession 0001815776-25-000071): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000071/lenz-20250930.htm
- SEC Form 10-Q (accession 0001815776-25-000056): "Based on these results, we selected LNZ100 as our lead product candidate, for which we submitted a New Drug Application ("NDA") to Food and Drug Administration ("FDA") in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000056/lenz-20250630.htm
- SEC Form 10-Q (accession 0001815776-25-000056): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000056/lenz-20250630.htm
- SEC Form 10-Q (accession 0001815776-25-000032): "Based on these results, we selected LNZ100 as our lead product candidate, for which we submitted a New Drug Application ("NDA") to Food and Drug Administration ("FDA") in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000032/lenz-20250331.htm
- SEC Form 10-Q (accession 0001815776-25-000032): "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000032/lenz-20250331.htm
- SEC Form 10-K (accession 0001815776-25-000019): "Based on these results, we selected LNZ100 as our lead product candidate, for which we submitted a New Drug Application ("NDA") to Food and Drug Administration ("FDA") in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000019/lenz-20241231.htm
- SEC Form 10-K (accession 0001815776-25-000019): "Based on these positive results in our Phase 3 trial, we selected LNZ100 as our lead product candidate and submitted an NDA to the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000019/lenz-20241231.htm
- SEC Form 10-K (accession 0001815776-25-000019): "Having successfully completed all three CLARITY trials, we submitted an NDA for LNZ100 to the FDA in August 2024 with a potential approval in mid-2025 and launch target date, if approved, in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000019/lenz-20241231.htm

### Oct 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: presbyopia, a condition.
- First seen 2025-03-19, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): "In October 2024, the Company announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000017): "In October 2024, the Company announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm

### July 31, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: presbyopia in adults.
- First seen 2025-07-31, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000069): "•Announced FDA approval of VIZZ for the treatment of presbyopia on July 31, 2025 as the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm
- SEC Form 10-Q (accession 0001815776-26-000059): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm
- SEC Form 10-Q (accession 0001815776-26-000052): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/lenz-20260630.htm
- SEC Form 10-Q (accession 0001815776-26-000037): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000037/lenz-20260331.htm
- SEC Form 10-K (accession 0001815776-26-000011): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/lenz-20251231.htm
- SEC Form 10-Q (accession 0001815776-25-000071): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched VIZZ commercially in the United States in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000071/lenz-20250930.htm
- SEC Form 10-Q (accession 0001815776-26-000059): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched such product commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm
- SEC Form 10-Q (accession 0001815776-26-000052): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched such product commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/lenz-20260630.htm
- SEC Form 10-Q (accession 0001815776-26-000037): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched such product commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000037/lenz-20260331.htm
- SEC Form 10-K (accession 0001815776-26-000011): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched such product commercially in the U.S. in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/lenz-20251231.htm
- SEC Form 10-Q (accession 0001815776-25-000071): "In July 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, and we launched such product commercially in the United States in August 2025." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000071/lenz-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000059): "SAN DIEGO, CA - July 31, 2025 - LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), today announced the US Food and Drug Administration ("FDA") approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000059/exhibit991-73125fdaapprova.htm

### August 8, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: presbyopia.
- First seen 2025-03-19, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000054): "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000054): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100 and noted it is not planning to hold an Advisory Committee Meeting to discuss this application." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000054): "Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): ""The first quarter of 2025 and recent period have continued to be extremely productive as we near our August 8, 2025 PDUFA and the potential launch of LNZ100 in the United States." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100 and noted it is not planning to hold an Advisory Committee Meeting to discuss this application." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): "LENZ Therapeutics continues to make strong progress in its U.S. commercial preparations for LNZ100, its investigational treatment for presbyopia, as the Company approaches the August 8, 2025 PDUFA target action date." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000030): "The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000017): "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000017): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000017): "The Commercial team advanced its commercial readiness for LNZ100 for the treatment of presbyopia as the Company progressed towards the August 8, 2025 PDUFA target action date." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm
- Press release filed with the SEC (EX-99) (accession 0001815776-25-000017): "The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100." https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm

## Same indication

- [APX3330](https://sec-api.dev/pdufa/apx3330) (IRD)
- [MR-141](https://sec-api.dev/pdufa/mr-141) (VTRS)
- [RYZUMVI (ryzumvi)](https://sec-api.dev/pdufa/ryzumvi) (IRD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lnz100.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LNZ100 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lnz100

```bibtex
@misc{secapidev_pdufa_lnz100_20261116,
  title        = {LNZ100 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lnz100}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lnz100_20261116","title":"LNZ100 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lnz100","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
